Cancer is the top cause of death globally. Breast cancer is the most recurrent invasive cancer in women, and it is the second primary cause of death in women, followed by lung cancer. According to the American Cancer Society, around 41,760 women had breast cancer in 2020. The high prevalence of cancer, increasing geriatric cancer, and availability of advanced targeted therapies for cancer is anticipated to drive the market's growth. Several companies innovate and launch novel services and products through research and development (R&D) activities to develop various treatment products.
Access Full Report @ https://www.databridgemarketresearch.com/fr/reports/global-cancer-treatment-market
Data Bridge Market Research analyses that the Global Cancer Treatment Market is growing with a CAGR of 12.1% from 2022 to 2029 and is expected to reach USD 524,921.84 million by 2029 from USD 215,900.00 million in 2021. The increasing demand for the cancer treatment will provide potential opportunities for the market growth in the forecast period.
Increasing prevalence of cancer is anticipated to drive the market's growth rate
Breast cancer is the most common recurrent invasive cancer in women, and it causes the second leading cause of death in women after lung cancer. According to the American Cancer Society, around 41,760 women had breast cancer in 2020. Breast cancer starts quite small, to be felt or detected at an early stage. For instance, in 2018, as per the World Health Organization, it is anticipated that globally 9.6 million deaths were caused due to cancer. Additionally, 1 in 6 deaths is caused due to cancer. Approximately 70% of cancer deaths occur in low and middle-income countries
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Cancer Type (Breast Cancer, Colorectal Cancer with Liver Metastases, Lung Carcinoma, Prostate Cancer, Ovarian Cancer, Head-And-Neck Cancer, Pancreatic Cancer, Glioblastoma, Renal Cell Carcinoma, Anaplastic Thyroid Carcinoma, Sarcoma, and Others), Treatment (Medication, Targeted Therapies, Radiotherapy, Surgery, and Others), Route of Administration (Injectable, Oral, and Others), End User (Hospitals, Specialty Clinics,)
|
|
Countries Covered
|
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Abbott (U.S.), Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (U.S.), Quest Diagnostics Incorporated. (U.S.), Hologic, Inc. (U.S.), BD. (U.S.), GSK plc. (U.K.), Novartis AG (Switzerland), Bristol-Myers Squibb Company (U.S.), Lilly (U.S.), Pfizer, Inc. (U.S.), Genomic Health, Inc. (U.S.), Biomérieux (France), Astellas Pharma Inc. (Japan) and Myriad Genetics, Inc. (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
The cancer treatment market is categorized into four notable segments based on cancer type, treatment, route of administration, and end user.
- On the basis of cancer type, the cancer treatment market is segmented into breast cancer, colorectal cancer with liver metastases, lung carcinoma, prostate cancer, ovarian cancer, head-and-neck cancer, pancreatic cancer, glioblastoma, renal cell carcinoma, anaplastic thyroid carcinoma, and sarcoma.
The breast cancer segment of cancer type segment is anticipated to dominate the cancer treatment market
The breast cancer segment is expected to dominate the market with 18.1% market share because of increasing government initiation and government campaign activities for raising awareness and early detection and treatment regarding breast cancer.
- On the basis of treatment, the global, Europe, Australia, U.S. cancer treatment market is segmented into medication, targeted therapies, radiotherapy, surgery, and others.
The medication segment of treatment segment is anticipated to dominate the cancer treatment market
The medication segment is expected to dominate the market with 39.3% market share because of growing product launches, increasing FDA approval for various types of drugs, and the strong presence of pipeline products.
- On the basis of route of administration, the market is segmented into injectable, oral and others. The injectable segment is expected to dominate the market with 55.9% market share because of the wide availability of mostly cancer treatment in injectable form.
- On the basis of end user, the cancer treatment market is segmented into hospitals & specialty clinics. The hospitals segment is expected to dominate the market with 59.0% market share since wealthy hospitals in developed and developing countries demand advanced cancer treatment.
Major Players
Data Bridge Market Research recognizes the following companies as the major cancer treatment market players in cancer treatment market are Abbott (U.S.), Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (U.S.), Quest Diagnostics Incorporated. (U.S.), Hologic, Inc. (U.S.), BD. (U.S.), GSK plc. (U.K.), Novartis AG (Switzerland), Bristol-Myers Squibb Company (U.S.), Lilly (U.S.), Pfizer, Inc. (U.S.), Genomic Health, Inc. (U.S.), Biomérieux (France), Astellas Pharma Inc. (Japan) and Myriad Genetics, Inc. (U.S.).
Market Development
- In 2020, Myovant Sciences announced that it had received U.S. Food and Drug Administration (U.S. FDA) approval for its new drug ORGOVYX used for the treatment of patients with advanced prostate cancer. It is the first and only oral gonadotropin-releasing hormone receptor antagonist that is developed for men who have advanced prostate cancer.
- In 2020, MacroGenomics, Inc. announced that it has received U.S. Food and Drug Administration approval for its new drug application MARGENZA, along with chemotherapy for the patients who have breast cancer who have received two or more prior anti-HER2 regimens. This approval has helped the company portfolio to enhance sin the U.S. market.
Regional Analysis
Geographically, the countries covered in the cancer treatment market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in cancer treatment market during the forecast period 2022 to 2029
North America dominates the cancer treatment market due to the high prevalence of cancer. North America will also continue to dominate the market because of the high healthcare expenditure. The U.S. is expected to have a large market share due to the largest consumer market with high GDP, and many major market players present in the market
Asia-Pacific is estimated to be the fastest-growing region in cancer treatment market the forecast period 2022 to 2029
Asia-Pacific is expected to grow from 2022 to 2029 due to the growing government initiation and government campaign activities for raising awareness and early detection and treatment associated with breast cancer.
For more detailed information about cancer treatment market report, click here – https://www.databridgemarketresearch.com/fr/reports/global-cancer-treatment-market
